CSIMarket
 
Inari Medical Inc   (NASDAQ: NARI)
Other Ticker:  
 
 
Price: $79.3000 $-0.04 -0.050%
Day's High: $79.39 Week Perf: -0.19 %
Day's Low: $ 79.29 30 Day Perf: 44.05 %
Volume (M): 3,368 52 Wk High: $ 79.69
Volume (M$): $ 267,043 52 Wk Avg: $48.86
Open: $79.35 52 Wk Low: $36.73



 Market Capitalization (Millions $) 4,628
 Shares Outstanding (Millions) 58
 Employees 800
 Revenues (TTM) (Millions $) 572
 Net Income (TTM) (Millions $) -79
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 13

Inari Medical Inc
Inari Medical Inc. is a medical device company founded in 2013 and headquartered in Irvine, California. The company is dedicated to developing innovative technologies that improve the outcomes of patients with complex vascular disease. Inari Medical focuses on developing catheter-based intervention systems for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), which are the most common and serious forms of venous thromboembolism (VTE). The company's flagship product is the ClotTriever System, which is designed to remove large clot burdens from deep veins without the need for thrombolytic medication.

Inari Medical's ClotTriever System is a minimally invasive medical device that facilitates the rapid removal of large clots from deep veins in the legs. The device utilizes a vacuum-based system to physically remove the clot from the vein, which eliminates the need for thrombolytic drugs and reduces the risk of bleeding complications. The ClotTriever System is easy to use, and it can be performed in an outpatient setting with local anesthesia. This minimally invasive approach helps patients to recover more quickly and reduces the burden on hospitals.

Inari Medical has shown impressive growth in recent years, with the company's revenue increasing from $5 million in 2018 to $39 million in 2020. The company has attracted significant investment from venture capitalists, with two funding rounds raising a total of $234 million. In November 2020, Inari Medical completed an initial public offering (IPO) on the NASDAQ stock exchange, raising $156 million.

Inari Medical has also received regulatory approval from the U.S. Food and Drug Administration (FDA) for its ClotTriever System. The device was cleared for use in the United States in 2018, and further approvals have been granted in Europe, Japan, and other international markets. The company has also received several awards and recognitions for its innovation and impact on patient care.

Overall, Inari Medical is a rapidly growing medical device company that is dedicated to improving the outcomes of patients with complex vascular disease. With its innovative ClotTriever System, the company has demonstrated its ability to develop and market cutting-edge medical technologies that improve patient care, reduce healthcare costs, and enhance the quality of life for patients.


   Company Address: 6001 Oak Canyon Irvine 92618 CA
   Company Phone Number: 923-4747   Stock Exchange / Ticker: NASDAQ NARI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX     
BDX     
BSX     
MDT     
SYK     
ZBH     
• View Complete Report
   



Merger and Acquisition

Stryker to Acquire Inari Medical for $4.9 Billion, Enhancing Peripheral Vascular Portfolio and Addressing Growing Demand in VTE Solutions.,

Published Mon, Jan 6 2025 9:08 PM UTC

Stryker Announces Definitive Agreement to Acquire Inari Medical, Inc., Providing Entry into High-Growth Peripheral Vascular SegmentIn a significant development for the medical technology industry, Stryker Corporation (NYSE: SYK) announced on January 6, 2025, a definitive agreement to acquire Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, translating to a tota...

Clinical Study

Advancing DVT Care A Collaborative Effort in Revolutionizing Therapeutic Outcomes through the DEFIANCE Tri...

Published Tue, Oct 15 2024 12:01 PM UTC

In the evolving landscape of thrombosis management, new collaborations and technological advancements are pivotal in enhancing patient outcomes. On October 15, 2024, Inari Medical, Inc., a medical device company committed to transforming the lives of patients with venous and related diseases, announced its partnership with the American Venous Forum (AVF) and the National Blo...

Announcement

By In a noteworthy development that is sending ripples throughout the biotech investment commun...

Published Sun, Jun 30 2024 6:07 PM UTC

Shareholder Alert: Inari Medical Faces Class Action Lawsuit Amid Investor Concerns By In a noteworthy development that is sending ripples throughout the biotech investment community, Pomerantz LLP has announced the filing of a class action lawsuit against Inari Medical, Inc. (NASDAQ: NARI). This lawsuit signifies mounting discontent among investors concerning the company?s...

Announcement

Inari Medical Faces Class Action Suit as Revenue Soars 30.86% YoY

Published Fri, May 31 2024 3:31 PM UTC

Inari Medical Inc., a leading medical technology company focused on developing groundbreaking devices for the treatment of vascular diseases, has been hit with a class action securities lawsuit. The legal action was brought about by Levi & Korsinsky, LLP, a renowned New York-based law firm specializing in securities litigation. Investors in Inari Medical (NASDAQ: NARI) have ...

Announcement

Legal Turmoil Looms for Inari Medical Amidst Strong Revenue Growth

Published Tue, May 28 2024 6:42 PM UTC

Inari Medical Faces Class Action Amid Impressive Revenue Performance May 28, 2024 New York Inari Medical, Inc. (NASDAQ: NARI) is facing a class action lawsuit, filed by Pomerantz LLP, which has recently garnered significant attention within the financial and medical communities. The law firm announced the filing and is actively encouraging affected shareholders to reac...







Inari Medical Inc's Segments
United States    92.99 % of total Revenue
International    7.56 % of total Revenue
VTE    95.28 % of total Revenue
Emerging Therapies    5.27 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com